GRO Biosciences tackles ‘Holy Grail’ challenges, using non-standard amino acids to expand the amino acid palette
Last month, GRObio completed a $25-million Series A financing co-led by Leaps by Bayer and Redmile Group. Redmile is a San Francisco venture and private equity investment firm. Leaps is the equity investment arm of Bayer. Proceeds from the financing, GRObio said, will support development of its GRO platform, a scale-up of bioprocess manufacturing, preclinical validation studies, and IND-enabling studies for GRObio’s pipeline of NSAA protein therapeutics designed to treat autoimmune and metabolic diseases . . .